Glaucoma
Conditions
Interventions
Mono-therapy:Travoprost ophthalmic solution 0.004% for 3 months
Sponsors
I.CHANGE study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients whose baseline IOP of non medication is NTG<20 mmHg. 2.A patient given a diagnosis of NTG newly or the patient who does not start medical treatment in NTG. 3.Age at the time of the agreement 20 years old or older. 4.Gender is no object. 5.Outpatient or the hospitalization are no object.
Exclusion criteria
Exclusion criteria: 1.Complications with chronic or recurrent uveitis, scleritis, or corneal herpes. 2.History of ocular trauma or intraocular conventional surgery or laser ocular surgery in the study eye within 3 months before baseline examinations. 3.Any abnormality preventing reliable applanation tonometer in the study eye. 4.Known medical history of allergic to PGA. 5.Patients using an IOP-lowering drug other than those to be used in the study. 6.Patients using systemic administration of an oral CAI (Diamox, etc.) 7.Patient having serious eyes complications 8.Women who are pregnant or lactating. 9.Patients who are judged to be inappropriate for participation in the study for other reason by the doctor in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy IOP value; IOP-lowering effect from baseline (reduced value; reduction rate%) | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety 1.Ocular safety assessment:Conjunctival hyperemia, adverse events 2.Systemic safety assessment:adverse events | — |
Countries
Japan
Contacts
Public ContactTadashi Nakano
The Jikei University Ophthalmology
Outcome results
None listed